Literature DB >> 18985071

A novel matrix metalloproteinase 2 (MMP2) terminal hemopexin domain mutation in a family with multicentric osteolysis with nodulosis and arthritis with cardiac defects.

Beyhan Tuysuz1, Rebecca Mosig, Gürkan Altun, Selim Sancak, Marc J Glucksman, John A Martignetti.   

Abstract

Multicentric osteolysis with nodulosis and arthropathy (MONA, NAO (OMIM no. 605156)) is an autosomal recessive member of the 'vanishing bone' syndromes and is notable for the extent of carpal and tarsal osteolysis and interphalangeal joint erosions, facial dysmorphia, and the presence of fibrocollagenous nodules. This rare disorder has been described previously in Saudi Arabian and Indian families. We now report on the first Turkish family with MONA, further confirming the panethnic nature of this disease. Strikingly, and in addition to the previously noted skeletal and joint features, affected members of this family also had congenital heart defects. Molecular analysis identified a novel MMP2 inactivating mutation that deletes the terminal hemopexin domains and thus confirmed the diagnosis of MONA. On the basis of these findings, we suggest that cardiac defects may also represent a component of this syndrome and thus a physiologically relevant target of MMP-2 activity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18985071      PMCID: PMC2721823          DOI: 10.1038/ejhg.2008.204

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  30 in total

1.  International nosology and classification of constitutional disorders of bone (2001).

Authors:  Christine M Hall
Journal:  Am J Med Genet       Date:  2002-11-15

2.  Mutation of the matrix metalloproteinase 2 gene (MMP2) causes a multicentric osteolysis and arthritis syndrome.

Authors:  J A Martignetti; A A Aqeel; W A Sewairi; C E Boumah; M Kambouris; S A Mayouf; K V Sheth; W A Eid; O Dowling; J Harris; M J Glucksman; S Bahabri; B F Meyer; R J Desnick
Journal:  Nat Genet       Date:  2001-07       Impact factor: 38.330

3.  Dimorphic effects of Notch signaling in bone homeostasis.

Authors:  Feyza Engin; Zhenqiang Yao; Tao Yang; Guang Zhou; Terry Bertin; Ming Ming Jiang; Yuqing Chen; Lisa Wang; Hui Zheng; Richard E Sutton; Brendan F Boyce; Brendan Lee
Journal:  Nat Med       Date:  2008-02-24       Impact factor: 53.440

4.  Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1.

Authors:  G A McQuibban; G S Butler; J H Gong; L Bendall; C Power; I Clark-Lewis; C M Overall
Journal:  J Biol Chem       Date:  2001-09-24       Impact factor: 5.157

5.  Specific collagenolysis by gelatinase A, MMP-2, is determined by the hemopexin domain and not the fibronectin-like domain.

Authors:  M L Patterson; S J Atkinson; V Knäuper; G Murphy
Journal:  FEBS Lett       Date:  2001-08-17       Impact factor: 4.124

6.  Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3.

Authors:  G A McQuibban; J H Gong; E M Tam; C A McCulloch; I Clark-Lewis; C M Overall
Journal:  Science       Date:  2000-08-18       Impact factor: 47.728

Review 7.  New form of idiopathic osteolysis: nodulosis, arthropathy and osteolysis (NAO) syndrome.

Authors:  S M Al-Mayouf; M Majeed; C Hugosson; S Bahabri
Journal:  Am J Med Genet       Date:  2000-07-03

8.  GATA4 mutations cause human congenital heart defects and reveal an interaction with TBX5.

Authors:  Vidu Garg; Irfan S Kathiriya; Robert Barnes; Marie K Schluterman; Isabelle N King; Cheryl A Butler; Caryn R Rothrock; Reenu S Eapen; Kayoko Hirayama-Yamada; Kunitaka Joo; Rumiko Matsuoka; Jonathan C Cohen; Deepak Srivastava
Journal:  Nature       Date:  2003-07-06       Impact factor: 49.962

9.  NKX2.5 mutations in patients with congenital heart disease.

Authors:  Doff B McElhinney; Elizabeth Geiger; Joshua Blinder; D Woodrow Benson; Elizabeth Goldmuntz
Journal:  J Am Coll Cardiol       Date:  2003-11-05       Impact factor: 24.094

10.  Elevated glucose inhibits VEGF-A-mediated endocardial cushion formation: modulation by PECAM-1 and MMP-2.

Authors:  Josephine M Enciso; Dita Gratzinger; Todd D Camenisch; Sandra Canosa; Emese Pinter; Joseph A Madri
Journal:  J Cell Biol       Date:  2003-02-17       Impact factor: 10.539

View more
  15 in total

1.  Complementary interplay between matrix metalloproteinase-9, vascular endothelial growth factor and osteoclast function drives endochondral bone formation.

Authors:  Nathalie Ortega; Ke Wang; Napoleone Ferrara; Zena Werb; Thiennu H Vu
Journal:  Dis Model Mech       Date:  2010-02-08       Impact factor: 5.758

2.  Functional characterisation of a novel mutation affecting the catalytic domain of MMP2 in siblings with multicentric osteolysis, nodulosis and arthropathy.

Authors:  Jacopo Azzollini; Davide Rovina; Cristina Gervasini; Ilaria Parenti; Alessia Fratoni; Maria Vittoria Cubellis; Amilcare Cerri; Luca Pietrogrande; Lidia Larizza
Journal:  J Hum Genet       Date:  2014-10-02       Impact factor: 3.172

Review 3.  Multicentric osteolysis with nodulosis and arthropathy (MONA) with cardiac malformation, mimicking polyarticular juvenile idiopathic arthritis: case report and literature review.

Authors:  Filip Christian Castberg; Susanne Kjaergaard; Rebecca A Mosig; Mollie Lobl; Chiara Martignetti; John A Martignetti; Charlotte Myrup; Marek Zak
Journal:  Eur J Pediatr       Date:  2013-07-31       Impact factor: 3.183

4.  Emergence of a metalloproteinase / phospholipase A2 axis of systemic inflammation.

Authors:  Carlos Fernandez-Patron; Dickson Leung
Journal:  Metalloproteinases Med       Date:  2015-08-13

5.  Matrix metalloproteinase-2 negatively regulates cardiac secreted phospholipase A2 to modulate inflammation and fever.

Authors:  Evan Berry; Samuel Hernandez-Anzaldo; Farideh Ghomashchi; Richard Lehner; Makoto Murakami; Michael H Gelb; Zamaneh Kassiri; Xiang Wang; Carlos Fernandez-Patron
Journal:  J Am Heart Assoc       Date:  2015-03-27       Impact factor: 5.501

Review 6.  Patient with mutation in the matrix metalloproteinase 2 (MMP2) gene - a case report and review of the literature.

Authors:  Alka V Ekbote; Sumita Danda; Andreas Zankl; Kausik Mandal; Tina Maguire; Kobus Ungerer
Journal:  J Clin Res Pediatr Endocrinol       Date:  2014

Review 7.  Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Inflammation and Fibrosis of Skeletal Muscles.

Authors:  Hala S Alameddine; Jennifer E Morgan
Journal:  J Neuromuscul Dis       Date:  2016-11-29

8.  Identification of a Novel Heart-Liver Axis: Matrix Metalloproteinase-2 Negatively Regulates Cardiac Secreted Phospholipase A2 to Modulate Lipid Metabolism and Inflammation in the Liver.

Authors:  Samuel Hernandez-Anzaldo; Evan Berry; Vesna Brglez; Dickson Leung; Tae Jin Yun; Jun Seong Lee; Janos G Filep; Zamaneh Kassiri; Cheolho Cheong; Gérard Lambeau; Richard Lehner; Carlos Fernandez-Patron
Journal:  J Am Heart Assoc       Date:  2015-11-13       Impact factor: 5.501

9.  Bisphosphonates in multicentric osteolysis, nodulosis and arthropathy (MONA) spectrum disorder - an alternative therapeutic approach.

Authors:  Karin Pichler; Daniela Karall; Dieter Kotzot; Elisabeth Steichen-Gersdorf; Alexandra Rümmele-Waibel; Laureane Mittaz-Crettol; Julia Wanschitz; Luisa Bonafé; Kathrin Maurer; Andrea Superti-Furga; Sabine Scholl-Bürgi
Journal:  Sci Rep       Date:  2016-09-30       Impact factor: 4.379

10.  Multicentric Osteolysis, Nodulosis, and Arthropathy in two unrelated children with matrix metalloproteinase 2 variants: Genetic-skeletal correlations.

Authors:  Hanan Elsebaie; Mohamed Abdelhafiz Mansour; Solaf M Elsayed; Shady Mahmoud; Tamer A El-Sobky
Journal:  Bone Rep       Date:  2021-07-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.